Comparative effectiveness review of influence of pretransplant treatment and conditioning strategies on allogeneic stem cell transplant effectiveness for treatment of chronic myelogenous leukemia
HAYES, Inc.
Record ID 32016000977
English
Authors' recommendations:
Patients with chronic myelogenous leukemia (CML) have an overproduction of partially mature white blood cells of the myeloid lineage. High doses of chemotherapy and/or radiotherapy can destroy bone marrow producing the abnormal cells but normal cells are also affected. Allogeneic hematopoietic stem cell transplantation (HSCT) is a procedure that uses stem cells derived from the peripheral blood or bone marrow of matched related or unrelated donors, which are infused into the transplant recipient where they migrate to the bone marrow and help reestablish normal hematopoiesis. The goals of pretransplant conditioning regimens with chemotherapy drugs and immunosuppressants are to reduce the burden of tumor cells by inducing a graft-versus-leukemia effect while preventing graft rejection and severe immunosuppression using treatments with varying intensities.
Relevant Questions: Do less intensive pretransplant conditioning regimens improve survival for CML patients undergoing allogeneic HSCT at least as effectively as myeloablative conditioning (MAC)? Does pre-HSCT treatment with the tyrosine kinase inhibitor imatinib or with interferon improve survival for CML patients? Do less intensive preconditioning regimens lead to a similar or higher rate of hematologic responses after allogeneic HSCT compared with MAC? How do pretransplant drug regimens and conditioning strategies for allogeneic HSCT compare in terms of safety? Have definitive patient selection criteria been established for the various conditioning regimens for HSCT for CML?
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
The report may be purchased from: http://www.hayesinc.com/hayes/crd/?crd=44886
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Stem Cell Transplantation
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2014 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.